Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.
You may also be interested in...
GSK Receives “Complete Response” Letter For Cervarix BLA
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
GSK Receives “Complete Response” Letter For Cervarix BLA
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.
FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix
Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.